ACIU:NSD-AC Immune SA (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.63

Change

-0.08 (-1.04)%

Market Cap

USD 0.55B

Volume

0.06M

Average Target Price

USD 11.00 (+44.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-1.13 (-0.41%)

USD72.21B 46.19 34.50
REGN Regeneron Pharmaceuticals, Inc

+34.20 (+6.29%)

USD61.35B 27.40 20.77
SGEN Seattle Genetics, Inc

-1.42 (-0.93%)

USD26.23B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+8.28 (+7.80%)

USD25.27B 9.58 8.24
INCY Incyte Corporation

+2.33 (+2.37%)

USD21.35B 47.64 35.20
MRNA Moderna, Inc

+3.36 (+6.44%)

USD20.62B N/A N/A
GMAB Genmab A/S

+1.28 (+4.31%)

USD20.17B 53.85 5.58
BMRN BioMarin Pharmaceutical Inc

-1.10 (-1.03%)

USD19.30B 164.67 98.79
ALNY Alnylam Pharmaceuticals, Inc

-0.25 (-0.19%)

USD15.31B N/A N/A
GLPG Galapagos NV

+3.68 (+1.86%)

USD12.68B 70.13 37.04

ETFs Containing ACIU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.45% 40% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.45% 39% F 54% F
Trailing 12 Months  
Capital Gain 44.23% 70% C- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 44.23% 70% C- 85% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.51% 34% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.51% 33% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 33.52% 83% B 55% F
Risk Adjusted Return -22.41% 28% F 14% F
Market Capitalization 0.55B 66% D 64% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.63 42% F 62% D-
Price/Book Ratio 1.95 79% C+ 50% F
Price / Cash Flow Ratio 10.02 7% F 29% F
EV/EBITDA 4.91 35% F 81% B-
Management Effectiveness  
Return on Equity -10.18% 92% A- 40% F
Return on Invested Capital 19.74% 94% A 92% A-
Return on Assets -4.77% 91% A- 33% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.63 45% F 29% F
Short Percent 2.19% 72% C- 60% D-
Beta 0.49 86% B 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.